Strategic Partnerships

In September 2015, Nurix entered an exclusive collaboration with Celgene for the discovery and development of next-generation therapies targeting E3 ubiquitin ligases in oncology, immunology and inflammation. The collaboration is focused on advancing novel therapies that directly manipulate E3 ligases to control protein levels. Celgene is a global leader in developing and commercializing therapies targeting the ubiquitin proteasome system.